| 【Company Research】Innovent Biologics (1801 HK) – Mazdutide (IBI362) to become the best GLP-1 drug for obesity in China |
| 【Company Research】FIT Hon Teng (6088 HK) – Weak 1Q23 as expected; Expect multiple drivers from iPhone/CPU socket/400G/EV in 2H23E |
| 【Company Research】JD.com (JD US) – Focusing on driving healthy and quality growth |
| 【Fixed Income Research】Chinese TMT: Buy XIAOMI 0’27 (CB), XIAOMI 30-31s, MEITUA 0’27 (CB) and PDD 0’25 (CB) |
| 【Company Research】JS Global Lifestyle (1691 HK) – 1Q23 results beat and gradual recovery is likely |
| 【Company Research】Li Auto Inc. (LI US) – 1Q23 beat with sustainable profitability ahead |
| 【Company Research】Prada SpA (1913 HK) – Re-rating is not over when Prada remains hugely sub-scale to its global peers; initiate at Buy |
| 【Company Research】InnoCare Pharma (9969 HK) – Eyes on next steps of orelabrutinib for MS |
| 【Company Research】Samsonite (1910 HK) – Another high growth year for Asia |
| 【Sector Research】China Consumer – From reopening to recovery – is the release of household excess savings the silver bullet? |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
